Angiotensin II receptor Inhibitors
3 drugsAbout Angiotensin II receptor
The Angiotensin II receptor is a key component of the renin-angiotensin-aldosterone system (RAAS), regulating blood pressure and fluid balance. As a receptor protein, it mediates vasoconstriction and aldosterone release, increasing blood pressure. Modulation of this receptor is a successful therapeutic strategy for cardiovascular conditions.
Blocking the Angiotensin II receptor lowers blood pressure and reduces cardiovascular event risk. Currently, there is no genetic evidence available linking the Angiotensin II receptor to specific diseases. The clinical success of existing drugs underscores its importance as a therapeutic target.
Three FDA-approved drugs target the Angiotensin II receptor, including EXFORGE, AZOR and EXFORGE HCT, all small molecules. These drugs, developed by Novartis and COSETTE, are used in cardiovascular therapeutic areas. EXFORGE was the first approved drug in 2007.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Obesity with only 1 trials.
Top Angiotensin II receptor Drugs
Novartis and COSETTE are the only two companies with approved drugs targeting this receptor.
The concentrated market suggests high barriers to entry or limited innovation by other players.
Angiotensin II receptor Drug Modality Landscape
Modalities
Routes of Administration
Angiotensin II receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
Angiotensin II receptor Clinical Trials 123 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 34 | 31 | 1 | 2 | 97% |
| Phase 2 | 15 | 12 | 1 | 2 | 92% |
| Phase 3 | 29 | 22 | 5 | 2 | 81% |
| Phase 4 | 45 | 27 | 10 | 8 | 73% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Angiotensin II receptor Drug Approval Timeline (2007 - 2009)
The first drug was approved in 2007, and the most recent in 2009, spanning a 3-year period.
The lack of recent approvals suggests a saturated market or challenges in developing new drugs for this target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 66 clinical trials targeting Angiotensin II receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities